Meanwhile, the BSE Sensex was up 7.45 points, or 0.09%, to 8,746.69.On BSE, 15,433 shares were traded in the counter. The stock had an average daily volume of 51,461 shares in the past one quarter.The stock hit a high of Rs 115 and a low of Rs 110.25 so far during the day. The stock hit a 52-week high of Rs 558 on 14 December 2007 and a 52-week low of Rs 101.60 on 6 November 2008.
The small-cap stock had underperformed the market over the past one month till 2 December 2008, declining 8.75% as compared to the Sensex's decline of 10.72%. It had also nderperformed the market in the past one quarter, falling 63.92% as compared to the Sensex's decline of 41.93%.The company's current equity is Rs 26.88 crore. Face value per share is Rs 5.
As per reports, Eli Lilly and Co has sued Aurobindo Pharma in the US district court after the later filed abbreviated new drug applications (ANDA) with US Food & Drug Administration (US FDA) for marketing approval for Eli Lilly's top selling anti-depressant drug Cymbalta in the US.Cymbalta is the second largest revenue earner for Eli Lilly at about $2.3 billion for the 12 months ended September 2008.
Aurobindo Pharma had in November 2008 received final approval from US FDA for manufacturing and marketing Sertraline hydrochloride in 20-miligram strength.The company had in October 2008 received US FDA approval to manufacture and market Cyclobenzaprine hydrochloride tablets in multiple strengths.
Aurobindo Pharma reported a net loss of Rs 38.50 crore in Q2 September 2008 as compared to net profit of Rs 100.92 crore in Q2 September 2007. Net sales rose 2.1% to Rs 624.68 crore in Q2 September 2008 over Q2 September 2007.Aurobindo Pharma is engaged in developing, manufacturing and marketing active pharmaceutical ingredients, intermediates and generic formulations.
No comments:
Post a Comment